Crinetics Pharmaceuticals, a clinical-stage biotech developing oral therapies for rare endocrine diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The San Diego, CA-based company was founded in 2008 and plans to list on the Nasdaq under the symbol CRNX. J.P. Morgan, Leerink Partners and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
